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Assessing the transport of receptor-mediated drug-delivery 
devices across cellular monolayers
Erik Brewera and Anthony M. Lowmanb
aDrexel University, 3201 Chestnut Street, Philadelphia, PA 19104 USA
bRowan University, 201 Mullica Hill Rd Glassboro, NJ 08028 USA
Abstract
Receptor-mediated endocytosis (RME) has been extensively studied as a method for augmenting 
the transport of therapeutic devices across monolayers. These devices range from simple ligand-
therapeutic conjugates to complex ligand-nanocarrier systems. However, characterizing the uptake 
of these carriers typically relies on their comparisons to the native therapeutic, which provides no 
understanding of ligand or cellular performance. To better understand the potential of the RME 
pathway, a model for monolayer transport was designed based on the endocytosis cycle of 
transferrin, a ligand often used in RME drug-delivery devices. This model established the 
correlation between apical receptor concentration and transport capability. Experimental studies 
confirmed this relationship, demonstrating an upper transport limit independent of the applied 
dose. This contrasts with the dose-proportional pathways native therapeutics rely on for transport. 
Thus, the direct comparison of these two transport mechanisms can produce misleading results 
that change with arbitrarily chosen doses. Furthermore, transport potential was hindered by 
repeated use of the RME-cycle. Future studies should base the success of this technology not on 
the performance of the therapeutic itself, but on the capabilities of the cell. Using receptor-binding 
studies, we were able to demonstrate how these capabilities can be predicted and potentially 
adopted for high-throughput screening methods.
Keywords
Monolayer; Receptors; Drug delivery systems; Passive diffusion/transport; Targeted drug 
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1. Introduction
Ligand-receptor interactions have long been utilized for drug delivery systems due to a 
number of beneficial traits they possess: therapeutics utilizing this interaction circumvent P-
glycoprotein (P-gp) efflux transporters, the key mechanism responsible for multi-drug 
resistance; their high specificity allows for site-specific targeting; the ligands illicit low 
immunological responses; and receptor-mediated endocytosis (RME) permits intra- and 
transcellular passage of large molecules which would normally be prevented from 
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permeating the cell wall[1–3]. Drug-delivery and nanomedical devices tethered to ligands 
have successfully taken advantages of these traits in a variety of applications: nanoparticles 
coated with cancer-specific ligands have been used to image early and developed tumours 
and detect peripheral metastases[4–6]; therapeutics have been directed to target cell-specific 
receptors to achieve localized delivery[7–9]; chemotherapeutic and gene transfection agents 
are made more effective when delivered within the intracelleular endosomal pathway[9–14].
RME has also been extensively studied as an alternate route across cell monolayers barriers, 
like those found in the gastrointestinal (GI) tract and the blood-brain barrier (BBB)[15, 16]. 
The cells that make up these monolayers are joined by tight junctions, forming a continuous 
wall that limits the diffusion of protein therapeutics due to their low lipid solubility and high 
molecular size, resulting in their poor bioavailability[17]. RME offers an attractive alternate 
route that relies on energy driven processes of the cell to transport the therapeutic.
The success of therapeutic-ligand conjugates and therapeutic nanocarrier-ligand devices 
have been reported using a variety of assessment methods. In vitro studies often describe the 
ability of drugs to traverse these monolayers by measuring the apparent permeability, Papp, a 
measure of the transcellular flux normalized with respect to the initial dose and monolayer 
surface area[18–20]. A more simple analysis, but also dose-normalized, is to report the 
percentage of the initial dose transported[21]. More absolute measurements report the total 
accumulation of the conjugate or nanoparticles across the monolayer[18, 22, 23]. In vivo 
measurements mirror many of the latter examples, such as percent transported and drug 
accumulation[24–26]. More often, the response of the drug is measured, rather than the drug 
directly, which introduces many specialized assessment methods[27–29]. In oral delivery, 
RME-devices are often assessed on their bioavailability, a ratio of the oral dose area-under-
the-curve (AUC) to the intra-venous AUC, both normalized to their respective doses[23, 30, 
31].
Normalizing the transport or response of a therapeutic, as seen in the Papp, the percent 
transported, and in the bioavailability, is useful in cases where poor permeability is expected 
and higher drug concentrations are required to obtain a measurable response[32]. It also 
allows for comparisons across a variety of experimental methods. In all cases, the RME-
drug systems are compared to the transport of the native drug, the non-targeted nanoparticle, 
or both, to show the improvement on the delivery method. This helps answer the question 
“how well do these devices improve the uptake or response of the therapeutic?” However, 
the therapeutics in these cases are simply cargo traveling with the ligand, and the relative 
efficacy of a drug compared to the drug travelling along these pathways gives no indication 
of ligand performance or potential. Therefore, we propose an alternative question: “What are 
the transport capabilities of the RME pathway?”
To answer this, we evaluated the performance of a representative ligand, transferrin (Tf), 
within the context of therapeutic monolayer transport. A mathematical model of Tf transport 
was adapted from existing models and kinetic data in literature to help understand the 
parameters important to transcytosis. We hypothesize that determining the benchmark for 
successful ligand uptake will help determine the capabilities for further usage in drug 
delivery devices and expose the limitations of currently used evaluation methods.
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2. Materials and Methods
2.1 Materials
Anti-rabbit transferrin antibody was purchased from Polysciences, Inc. (Warrington, PA). 
Human transferrin (Tf) and all other chemical reagents were purchased from Sigma 
Chemical Co. (St. Louis, MO). Non-reagent components were purchased from Fisher 
Scientific (Pittsburgh, PA).
Tf-iron saturation was performed according to the method developed by Klausner et al.[33] 
and confirmed using a Tecan Infinite M500 plate reader (Männedorf, Switzerland). All 
samples with an A465/A280 ratio above 0.045 were considered iron-saturated. Biotinylation 
was achieved using the NHS-biotin reagent, as outlined previously[34]. Briefly, Tf was 
dissolved in a phosphate buffer (0.1M sodium phosphate, 0.15M NaCl, pH 7.5) at 5mg/ml. 
NHS-Biotin was added at a 15x molar excess and reacted for 60min at room temperature. 
The reaction was then purified using gel filtration columns. Biotin content was analyzed 
using the HABA assay[35] and typically ranged from 3–5mol biotin/mol Tf.
Buffers and components for cell culture media were obtained from Invitrogen (Green Island, 
New York), with the exception of fetal bovine serum (FBS), which was obtained from 
Gemini Bio-Products (West Sacramento, California). Growth media consisted of Dulbecco’s 
Modified Eagle Medium (DMEM) with 10% FBS and 1% non-essential amino acids, except 
where noted.
2.2 Cell culture
All experiments were performed using CaCo-2 cells obtained from Sigma Aldrich with 
passage number ranging from 45–55. Cells were grown until reaching 80% confluency, after 
which they were collected for the binding studies or seeded for the transport studies. For the 
transport studies, 12-well Corning (Tewksbury, Massachusetts) Transwell® plates with 
0.4μm pores were seeded with approximately 50,000 cells. Cells were fed every other or 
third day. Tight junction development was monitored by measuring the trans-epithelial 
electrical resistance (TEER) with an epithelial voltohmmeter (EVOM2, World Precision 
Instruments, West Haven, CT). TEER values typically plateaued after three weeks, around 
800 Ω·cm2, indicating fully developed tight junctions.
2.3 Kinetic and Binding Sites Analysis
Kinetic binding data was obtained according to the procedure outlined by Vieira[36]. 
Briefly, various concentrations of Tf-biotin were incubated with CaCo-2 cells at 4°C in a 
HEPES buffer (20mM HEPES-NaOH, 100mM NaCl, 0.1% BSA, pH 7.5) until receptor 
binding reached equilibrium, about 4hrs. A low temperatures buffer was used to halt the 
endocytosis cycle and ensure only surface-bound receptors were counted[37]. Control 
samples, representing binding not specific to the Tf receptor, received a 100x molar excess 
of unlabeled Tf. The cells were then quickly centrifuged and washed repeatedly with ice-
cold buffer, until no un-bound Tf remained. The cells were then treated with a lysing 
solution (1mM EDTA, 50mM NaCl, 10mM Tris-HCl, 0.1% SDS, 1% Triton X-100, 0.2% 
BSA, pH 7.4). The lysate solution was then analyzed using the avidin/biotin ELISA assay 
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outlined in the same procedure to determine bound Tf. Specific binding, or binding 
associated with the Tf receptor, was calculated from the difference between total binding 
and control samples.
The association constant and binding-site density were calculated using non-linear 
regression analysis using the following model[38, 39]:
Eq. 1
Here, Y represents the amount of receptor-bound Tf, X the concentration of total Tf in the 
incubation media, Bmax the concentration of binding sites, and Ka the association constant.
2.4 Transport Studies
Prior to the start of transport studies, culture media were removed from the Transwell® trays 
and the wells washed three times with Hanks Buffered Saline Solution (HBSS). The cells 
were then incubated with HBSS for 1hr to deplete intracellular Tf levels leftover from the 
serum, after which the buffer was then removed. Fresh HBSS was added to the basolateral 
chamber of the wells, while HBSS with Tf-biotin was added to the apical side. Apical 
concentrations were 1μg/ml, 10μg/ml or 50 μg/ml. Control samples representing non-
specific transport contained a 100x molar excess of unlabeled Tf. Samples were then taken 
at 30min, 60min, 90min, 120min, 180min, and 240min time points, with fresh HBSS added 
to replenish the sampled amount. The studies were completed at 37°C. Specific transport, or 
transport associated exclusively with the Tf-receptor pathway, was calculated from the 
difference between the total transport and control samples.
Short-term repeat dose studies were conducted to mimic doses given in quick succession, 
and were performed as follows: transport trays were incubated with HBSS containing 
10μg/ml Tf-biotin for 4hrs, to mimic a transport study, although no samples were taken. The 
cells were then washed three times and incubated with growth media for 2hrs. The cells 
were washed again, incubated with HBSS for 1hr, and washed a final time. The transport 
study was then conducted as previously described. Long-term studies were conducted to 
mimic continual use of the Tf pathways. To accomplish this, cells seeded on Transwell® 
plates were fed with growth media supplemented with Tf at a concentration at 10μg/ml 
during the period of tight junction development, approximately 3 weeks. A repeat of the 
10μg/ml transport study was then conducted. A complimentary scatchard study was 
performed on cells grown continuously for the same period with the same modified growth 
media.
2.5 Statistical Analysis
The results of each study are reported and plotted as the mean ± one standard deviation. 
Statistical differences were determined using ANOVA followed by post-hoc analyses, where 
p values of <0.05 were considered significant.
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3. Adaptation of Transport Model
One of the most commonly used approaches for modeling biological systems is to outline 
discrete steps in terms of ordinary differential equations (ODEs)[40]. This method is widely 
used to describe the receptor-mediated process, with notable examples seen in studies 
involving the transferrin receptor[41], folic acid[42], low-density lipoprotein[43, 44], and 
epidermal growth factor (EGF)[45, 46]. Such models vary in complexity depending on their 
intended use. Detailed models, such as those for EGF which outline 25 or even 125 discrete 
steps[47, 48], provide a comprehensive and systematic understanding of the biomechanics of 
an entire ligand-receptor cycle. However, the large number of fitting parameters required in 
these cases tend to result in poorer performance in pharmacokinetic analyses, which prefer 
reduced models[49]. In the case of EGF, many of the underlying steps can be combined into 
a simpler 7-step process[50], focusing the model on the parameters relevant to the efficacy 
of the ligand therapeutic.
Here, we have adopted the outline of a reduced RME-model developed by Krippendorf et al.
[49] for the transferrin cycle in a cell monolayer geometry. The steps described by 
Ciechanover et al. are listed as follows[51]: iron-saturated Tf (Tf-Fe) binds with the surface 
receptor (TfR); The Tf-TfR complex then becomes internalized, creating an endosome; The 
higher pH of the endosome compartment causes Tf-Fe to shed its iron molecules, which are 
deposited within the cell; The endosome then returns to the cell surface, where the iron-free 
Tf is released to be reutilized.
Unlike previous models, the geometry and “barrier” effect of the monolayer creates 
distinguishable apical and basolateral processes and species, designated with “A” and “B” 
subscript in our adaptation in figure 1. Here, the initial binding of Tf-Fe [L+] and reversible 
release occurs at step (1) on the apical side and basolateral side, creating the complex [RL+]. 
These are then internalized in step (2), where the internalized complex [RL+]i sheds the iron 
molecules through step (3), becoming [RL]i. The surface recycling step occurs in step (4) 
and proceeds in both basolateral and apical directions. Non-ferrous Tf, [L], is then released 
in step (5).
Rate equations are derived to track the change of the various molecular species. For 
instance, the binding of apical Tf-Fe to its receptors in step (1) is written as follows:
Eq. 2
Reaction rates are then applied for the forward and reverse steps, and incorporated into 
ODEs for each species. For the rate equation of apical Tf-Fe, this is:
Eq. 3
All species are expressed in terms of molecules, and the terms VA, which is the volume of 
the apical chamber, and NA, Avogadro’s number, are included to express the free ligand as a 
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concentration. All reactions are first-order, with the exception of the second-order forward 
binding steps of Tf-Fe.
Rate constants were obtained from studies of the Tf cycle on the human hematoma line 
HepG2[41, 52], and are listed in Table 1. The starting conditions were chosen to simulate a 
typical unidirectional transport study[53]. The ODEs are then solved simultaneously using 
numerical integration if a number of assumptions are made: (1) the rate kinetics obtained 
from literature are similar to the those of the cells used in this study, (2) the receptor pool is 
split evenly between both sides, and (3) there is no receptor degradation or synthesis over 
the course of a transport study (the number of binding sites remains constant. For further 
analysis on the validity of these assumptions, please refer to the supplemental text. Ligand-
Receptor binding studies were performed to determine the starting concentration of binding 
sites.
4. Results
4.1 Number of Receptor Binding Sites
Figure 2 presents the equilibrium binding data of Tf with Caco-2 cells. Non-specific binding 
in control samples, representing binding through means other than the Tf receptor, increased 
in proportion with increasing concentration, while specific binding, the difference between 
the total Tf detected and control samples, levelled off. Non-linear regression analysis of the 
binding model (Eq. 1) was used to determine both the affinity of the ligand to the receptor, 
via the association constant Ka, and the binding site concentration. The association constant 
was calculated to be 1.2x108 M−1. The binding-site concentration, combined with the known 
concentration of cells in the binding solution, produced a binding site density of 1.08x106/
cell. For a 12-well transport tray containing approximately 386,000 cells when confluent and 
fully developed, this would result 323fmol of binding sites per side of the monolayer.
4.2 Model Simulation
With all starting conditions accounted for, a monolayer transport simulation was performed 
assuming an apical concentration of Tf-Fe of 10μg/ml, with the results plotted in Figure 3. 
The amount of free receptors on the apical side is immediately depleted at the beginning of 
the experiment due to the strong affinity and quick binding of the ligand at this 
concentration. The Tf-TfR complexes are then slowly internalized within the cells. This 
produces an initial sharp increase in internalized endosomes until after 6min, when the 
endosome concentration decreases as the recycling process becomes significant. Endosomes 
that accumulate on the basolateral side result in an increase in both basolateral receptors and, 
once the ligand is released, total basolateral Tf concentrations. Accumulation of basolateral 
Tf continues until apical receptors are exhausted, plateauing at 320fmol. Apical Tf, distinct 
from the original Tf-Fe, also accumulates in proportion with basolateral values (not shown 
in this graph), though receptors returning to this side are then free to transport Tf-Fe again.
In vitro transport studies were conducted with the same starting conditions alongside control 
samples with 100x-fold excess unlabeled Tf-Fe, the results of which are plotted in Figure 4. 
The excess unlabeled Tf-Fe saturates the available receptor sites, only allowing the labelled 
ligand to interact with the cell through non-specific mechanisms. These control samples 
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served three purposes: (1) to verify the integrity of the monolayer, (2) to distinguish between 
total and RME transport, and (3) to serve as a model for non-specific therapeutic uptake. 
Control samples resulted in a linear accumulation of Tf in the basolateral chamber, 
averaging 45±15fmol of total transport. The apparent permeability coefficient (Papp) was 
calculated to be 2.9±0.8x10−8cm/s. This verified that the monolayer was fully developed, as 
the Papp for typical monolayer integrity markers, such as mannitol (1.2x10−7cm/s)[54] or 
lucifer yellow (1x10−6cm/s)[55], are higher in magnitude. Total transport peaked at 
344±27fmol. Specific uptake, determined from the difference between the total and non-
specific transport, was found to rise sharply rise before plateauing at 298±22fmol, as 
expected from the model. This level was below the value predicted by the binding site 
density study (323fmol). Since levels of apical receptor binding sites correlated with 
basolateral Tf transport, starting conditions were modified to reflect the new value and the 
simulations repeated. However, experimental values for basolateral accumulation showed a 
lag of approximately Δt=0.5hr. To compare the results of the two, the output of the model 
was shifted by Δt to overlay with the experimental values.
4.3 Dose Study
As many drug delivery assessment methods assume dose proportionality and utilize 
normalization, we wished to conduct a transport study with a starting apical Tf-Fe 
concentration of 1μg/ml and 50μg/ml and compare it to the previous 10μg/ml study. The 
results are plotted in Figure 5. Here, non-specific uptake of the 1 μg/ml study was below our 
ELISA’s detection limit of 10fmol, while uptake of the 50μg/ml study reached as high as 
255±18fmol. Specific RME-transport sharply increased in both studies, starting at the time-
lag 0.5hr mark, before plateauing after 1.5hr at 293±20fmol with 1μg/ml and 308±34 with 
50μg/ml, the differences negligible from the 10μg/ml study.
4.3 Short-term Repeat Transport Study
Model simulations indicated that maximum basolateral transport ended with the complete 
polarization of the available receptor pool: receptors initially on the apical side were 
deposited to the basolateral side, resulting in an imbalance of receptor distribution. To test 
how this would impact further transport, consecutive transport studies were conducted with 
short incubation times (Figure 6) and compared against previous results (Figures 4 and 5). 
Briefly, the steps are as follows: (1) mock 4hr transport study at 10μg/ml, (2) 2hr incubation 
in cell culture media, (3) 1hr HBSS incubation, and (4) repeat 4hr transport study at 
10μg/ml. Non-specific uptake increased linearly with respect to time, reaching a maximum 
of 48±9fmol at 4hr. Maximum transport reached 173±9fmol, while specific RME-transport 
reached a plateau of 126±25fmol, both values significantly lower than the previous 10μg/ml 
study. To determine the cause of this drop in RME capacity, a model simulation was 
performed to track the movement of apical receptors across these two studies (Figure 7). As 
expected, the initial drop in total receptors (bound and unbound) occurs until all 298fmol 
receptors are exhausted and transport is halted at around the 1hr, followed by the plateau. 
When the study is halted and culture media is added to both apical and basolateral chambers, 
the receptors are transported in the reverse direction over the course of 2hrs. However, this 
only restores approximately 121fmol of receptors. During a further 1hr buffer incubation 
time, remaining intracellular receptors recycle to each side, resulting in a slight increase of 
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apical receptor levels to 127fmol, a 58% reduction from initial receptor levels. This results 
in decreased transport capabilities.
4.4 Long-term Repeat Transport Study
Full utilization of the available receptor pool requires their complete saturation over the 
course of the study. We wished to determine the long-term effects of receptor saturation on 
the transport capabilities of Tf by growing monolayers in culture media with supplemented 
human Tf during the tight junction development stage. A transport study with an apical 
concentration of 10μg/ml was then conducted as done previously (Figure 8). Accumulation 
of Tf via non-specific uptake reached a maximum of 51±10fmol after 4hrs, while total 
transport reached a maximum of 300±26fmol. Specific RME transport reached a plateau of 
247±38fmol after 1.5hrs, a 17% reduction for our initial 10μg/ml study.
To determine what effects this has on the receptor pool, binding-site analyses were 
performed on cells grown in the same supplemental media for the same length of time, 
(Figure 9). Non-linear regression analysis returned new fitting parameters, and showed the 
cells contained 8.82x105 binding sites/cell. Using Fischer’s F-test to test this new parameter 
on the original data[56], it was determined that the 18% drop in binding sites was significant 
(p=0.0017). In contrast, the new association constant, 1.24x108 M−1, was not significantly 
different from the original value.
5. Discussion
5.1 Adopted Model
The purpose of using literature RME-models was to gain insight on the important 
parameters governing the transcytosis across monolayers and how these parameters 
influence the assessment of drug-delivery devices utilizing this pathway. The model 
established the importance of the receptor in trafficking Tf across the monolayer, 
specifically the correlation between basolateral ligand transport and apical receptor 
concentration. Therefore, trans-monolayer transport capabilities can be estimated using the 
known receptor pools. We showed two methods that can provide this number: scatchard 
analyses of binding data and transport studies themselves. Advantages of collecting binding 
data include the ability to use cells during the growth phase, enabling for faster experiments 
and larger volumes, and flexibility in culture equipment. High-throughput screening 
methods have been extensively used for receptor-ligand binding data[57–59], and would 
ideally be used to screen for more advantageous ligand/cell pairings. Transport studies, 
despite being limited to specialized Transwell® trays and requiring longer culture periods, 
provide more direct data for drug-delivery studies, and can be tested alongside passive 
transport for comparison.
Experimental studies verified the results of the model, though two significant deviations 
were observed. First, experimental basolateral Tf levels lagged behind the model output by 
Δt, indicating the presence of one or more mechanisms not previously accounted for in 
literature models. Likely, apically internalized endosomes are not immediately available for 
basolateral recycling, and undergo further mechanisms before undergoing transcytosis. Tf 
has been found to enter two distinct initial endosome populations which may possess 
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different recycling mechanisms, though these have not undergone kinetic analyses[60]. 
Similar lag phenomena have been observed and accounted for in models regarding receptor 
signalling transduction[61] and virus pathogenesis[62]. However, these modeling methods 
are used to hide, not explain underlying biological mechanisms[63]. Since the lag did not 
affect the maximum transport potential and does not factor into the assessment methods 
being investigated, this was not investigated further.
Second, basolateral Tf levels were 7% lower than levels predicted from the model and 
receptor-binding studies. This difference can be attributed to the different cell growth stages 
used between the binding studies, which use cells grown in the exponential growth phase, 
and transport studies, where cells have entered a non-proliferative stage. Proliferating cells 
have been previously shown to have increased Tf-receptors levels, presumably due to their 
higher nutritional iron needs[64, 65], which results in an overestimate of receptors based on 
binding study results.
As our model includes no cellular mechanism for directing an internalized endosome to 
specific sides, simulations show that RME results in transport to both sides of the chambers. 
This is a hindrance to drug delivery devices targeting RME pathways across monolayers, 
because it is undesirable for ligands to return to the apical chamber, lowering the efficiency 
of these devices. However, this is typically not observed or reported, as the only 
distinguishing feature between starting and transported Tf species is the presence of iron. 
Spectroscopy methods lack the sensitivity to detect this, particularly at high apical 
concentrations[66], and labeling compounds are most often used to detect only the ligand 
itself. Radiolabeling methods have previously been used in studies of the Tf cycle to 
distinguish between iron, using the 59Fe isotope, and the ligand, using the 125I isotope[67–
70], which could be used here to confirm the results of the model. In addition, this technique 
could be used to distinguish between passively and RME-transported Tf within the same 
sample.
5.2 Transport Studies
A summary of the results is presented in Table 2, along with commonly observed 
assessment methods discussed previously: the percentage of dosed Tf to have been 
transported across via non-specific and combined pathways, the ratio of RME to passive 
transport ratio, and the total to passive transport ratio.
In comparing the results for non-specific transport in the variably dosed studies, we 
observed significant differences among their basolateral Tf accumulation, though when 
normalized to their applied dose, they showed no significant differences among them; this 
demonstrates the property of dose-proportionality, which implies that at any given time 
point above zero
Eq. 4
where [L]B in this case only relates to non-specific transport. In the repeat dose studies, non-
specific transport in both the short-term and long-term study demonstrated dose-
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proportionality as well, despite observed drops in receptor concentration. This demonstrates 
that the receptor has no influence on non-specific transport across the monolayer. 
Preliminary studies using media cooled to 4°C in controls, which shuts down ATP-driven 
processes, indicated that other active transport pathways were not a factor, and diffusion 
through the monolayer was the predominant mechanism behind non-specific transcytosis 
(data not shown).
In contrast, RME-transport remained unchanged in the variable dose studies, despite the 
changes in apical Tf concentration. This is because Tf outnumbered available receptors in all 
cases, making the receptor pool the limiting factor in specific transport. This mechanism 
leads to a lack of dose-proportionality, and is a common cause for nonlinear 
pharmacokinetics[71].
The repeat use of ligand transport was shown to adversely affect the available receptor pool 
on cells, decreasing RME- and overall transport. Short-term studies were designed to mimic 
dose-regiments requiring multiple daily uses of RME-drug delivery devices. Simulations 
showed that receptors travel to and from the basolateral side during the transport and 
equilibrium steps, but when equilibrium times were cut short, subsequent transport was 42% 
of its initial amount due to diminished apical receptor levels. Muro et al. had similarly found 
the slow recycling of the adhesion molecule ICAM-1 to result in diminished intracellular 
transport of drug delivery vehicles after short, successive dosing, but had believed ligands 
with faster transit times, like Tf, would be immune to this effect[72]. However, due to the 
geometry of the monolayer and the longer than expected transcellular recycling times, this 
was found not to be the case.
Long-term studies, designed to mimic continuous use of an RME-therapeutic system, also 
resulted in diminished transport (247±38). Accompanying binding-site analyses 
demonstrated that this is caused by a decrease in receptor pools. Previously, cells have 
shown to down-regulate their Tf-receptor levels in iron-rich culture media[50, 73, 74], while 
conversely up-regulating their receptor levels when deprived of iron[75, 76], which serves to 
control the uptake of iron in response to different environmental conditions. Originally, the 
source for iron is the endogenouse bovine-Tf present in the culture media, which has an 
affinity 165-fold less than that of human-Tf[77]. Furthermore, endogenous Tf levels are a 
mixture of diferric-, monoferric, and apo-Tf, with the latter two having affinities 4.4-fold 
less and 24-fold less than that of diferric-Tf, respectively[78]. In total, diferric-Tf typically 
only represent 10% of plasma Tf concentrations[79]. Thus, the addition of human differic-Tf 
to the culture media provides a much more potent iron transporter than endogenous bovine-
Tf level, resulting in receptor down-regulation. This feedback system is not exclusive to 
monolayer cell geometries, and affects surface and intra-cellular targeting devices as well. 
Thus, the efficacies of RME-based drug delivery devices are dependent on their dose 
regiment.
The dependence of the receptor in RME-transport processes, while having no role in passive 
ones, produces misleading results when directly comparing the two. When calculating the 
percentage of the available ligand that had been transported across the monolayer, the 
1μg/ml study appears to have the superior result, despite similar performances in the RME 
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transport process. The ratios of RME/passive and total/passive transport increases similarly 
with decreasing dose concentrations because the receptor availability remains unchanged. 
On the other hand, RME-transport levels decreased in both short- and long-term repeat 
studies due to drops in receptor levels, while consistent apical ligand concentrations resulted 
in unchanging passive-transport levels. This also produces results that appear inferior to the 
original 10μg/ml study, according to all three assessment methods, despite the studies 
receiving the same apical dose.
Furthermore, studies that only observe the total transport of RME-therapeutic drug delivery 
systems without proper controls fail to recognize that this is the result of the RME and non-
specific pathways occurring in tandem. Comparing these to the passive transport of the 
therapeutics will produce one of two outcomes: if the contribution of RME-transport is low, 
total transport will not appear different from the therapeutic alone; if RME-transport is 
significant, total transport will appear greater than the therapeutic. Thus, this method may 
not only be misleading, but also incapable of producing an inferior result.
6. Conclusions
The disagreements among the results in Table 2 highlight the fallacy in directly comparing 
passively transported therapeutics and RME-based therapeutic systems: ligand/receptor 
systems do not improve the passive uptake of therapeutics across monolayers; on the 
contrary, they occur within separate and independent transport routes. In this study, we 
demonstrated how a typical RME-drug delivery device is transported across a monolayer 
through both mechanisms simultaneously: (1) non specific-uptake, which occurs in a dose-
proportional manner, allowing for the use of dose-normalized concentration 
measurements[80, 81], and (2) the endocytosis pathways, which was shown to lack dose-
proportionality, and invalidating the assumptions inherent in typical assessment methods. 
The availability of receptors, and thus the performance of the delivery device, was further 
shown to change with repeated use of the cycle. Thus, while it is clear that RME systems 
have the potential to improve the overall transport of therapeutics, it is imperative that future 
research of these devices be evaluated within the context of the ligand and receptor’s 
capabilities and pharmacokinetics. These capabilities were predicted using simple receptor-
binding studies, which should be explored to screen for higher performing RME 
combinations.
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Figure 1. 
Transferrin cycle in a cell monolayer geometry. Subscripts “A” and “B” denote apical and 
basolateral species, respectively. The “+” superscript indicates full iron saturation of Tf. 
Steps
Brewer and Lowman Page 15
J Biomater Sci Polym Ed. Author manuscript; available in PMC 2015 May 22.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Figure 2. 
Receptor-ligand binding data of Tf to CaCo-2 cells
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Figure 3. 
Model simulation of Tf transport across CaCo-2 monolayer at 10μg/ml apical concentration
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Figure 4. 
Transport study at 10μg/ml Tf-Fe
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Figure 5. 
(A) Transport study at 1μg/ml Tf-Fe
(B) Transport study at 50μg/ml Tf-Fe
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Figure 6. 
Short-term repeat study
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Figure 7. 
Model simulation of apical receptor levels (difference from starting point). The stages 
shown are: (1) Initial 4hr transport study, (2) 2hr culture media equilibration, (3) 1hr Buffer 
equilibration, and (4) repeated 4hr transport study
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Figure 8. 
Long-term transport study
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Figure 9. 
Long-term receptor-ligand binding data of Tf to CaCo-2 cells
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Table 1
Kinetic Parameters
Parameter Rate constant Value
Binding of [L+] k1 (mol−1 min−1) 3.02 x 106
Dissociation of [RL+] k
−1 (min−1) 0.09
Internalization of [RL+] k2 (min−1) 0.20
Loss of irona k3 (min−1) 0.28
Recycling of [RL]ia k−4 (mol−1 min−1) 0.28
Dissociation of [LR] k
−5 (min−1) 2.60
a
From Ciechanover et al.[41], The iron-loss and recycling step are known to combine so that 1/0.14= 1/k3+ 1/k−4. These rates were assumed to be 
equal for the sake of the simulation.
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